KPV
KPV Tripeptide (Alpha-MSH Fragment)
KPV is a C-terminal tripeptide fragment (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (α-MSH), representing the core anti-inflammatory sequence of the parent peptide. It is primarily used for its potent anti-inflammatory, antimicrobial, and gut-protective properties, with particular interest in inflammatory bowel disease, wound healing, and systemic inflammation reduction. Unlike full-length α-MSH, KPV retains the immunomodulatory activity without the pigmentation and hormonal effects associated with melanocortin signaling.
Mechanism of Action
KPV exerts its effects primarily by binding to melanocortin receptors (MC1R and MC3R) on immune cells, inhibiting NF-κB activation and downstream pro-inflammatory cytokine production including TNF-α, IL-1β, and IL-6. It also directly enters cells via the PepT1 transporter in intestinal epithelial cells, allowing oral delivery with local gut activity and systemic uptake, where it suppresses NLRP3 inflammasome activation. Additionally, KPV demonstrates direct antimicrobial properties against pathogens such as Candida albicans and Staphylococcus aureus through membrane disruption mechanisms.
Evidence by Health Goal(15 goals)
Dosing Protocols
On empty stomach, at least 30 minutes before meals
Oral route is effective due to PepT1-mediated intestinal transport; particularly well-suited for gut-related indications such as IBD or intestinal permeability. Enteric-coated or delayed-release formulations may improve colonic delivery.
Morning or evening, consistent daily timing
Cycle: 8-12 weeks on, 4 weeks off
Subcutaneous injection provides reliable systemic bioavailability. Reconstitute lyophilized powder with bacteriostatic water. Rotate injection sites to minimize local tissue reactions.
Applied directly to affected skin area
Used for localized inflammatory skin conditions, wound healing acceleration, and antimicrobial applications. Penetration enhancers such as DMSO may improve dermal absorption.
Safety & Side Effects
KPV has a favorable safety profile in preclinical studies and early human research, with no significant toxicity observed at therapeutic doses and a well-tolerated administration profile across routes. However, human clinical trial data remains limited, long-term safety is not well-characterized, and it is sold as a research compound only in most jurisdictions, meaning quality control and purity can vary significantly between vendors.
Possible Side Effects
- !Mild injection site redness or irritation with subcutaneous administration
- !Transient gastrointestinal discomfort or loose stools, particularly at higher oral doses
- !Mild nausea at doses exceeding 1000mcg orally
- !Temporary skin flushing reported in rare cases with systemic dosing
- !Potential for localized skin irritation with topical formulations in sensitive individuals
- !Theoretical immunosuppressive risk with prolonged use in immunocompromised individuals
Interactions
- -May potentiate the effects of corticosteroids or other immunosuppressants - combination could result in excessive immune suppression
- -Potential additive anti-inflammatory effect with NSAIDs; monitor for enhanced immunomodulation
- -May interact with biologic therapies targeting TNF-α or IL-1 pathways (e.g., adalimumab, anakinra) due to overlapping mechanisms
- -Could theoretically reduce efficacy of vaccines or immune challenges during active use due to cytokine suppression
- -PepT1 transporter competition with other di/tripeptide-based drugs (e.g., beta-lactam antibiotics) when taken orally at the same time
Cost & Where to Buy
Research-grade KPV from reputable peptide vendors typically costs $30-80 per vial (5-10mg). Monthly cost depends heavily on dose, route, and vendor purity standards. Oral capsule formulations from compounders are available but less common. Always verify third-party COA and HPLC purity above 98%.
Search on Amazon